Previous 10 | Next 10 |
PTC Therapeutics, Inc. (PTCT) Q1 2021 Results Conference Call May 04, 2021 04:30 PM ET Company Participants Kylie O'Keefe - Senior Vice President Commercial and Corporate Strategy Stuart Peltz - Chief Executive Officer Matthew Klein - Chief Development Officer Eric Pauwels - Chief Business Of...
PTC Therapeutics (PTCT): Q1 GAAP EPS of -$1.83 misses by $0.28.Revenue of $117.94M (+72.8% Y/Y) beats by $18.16M.PTC Reaffirms Full Year 2021 Guidance as Follows:PTC anticipates net product revenues for the DMD franchise for the full year 2021 to be between $355 and $375 million.PTC anticipat...
PTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Financial Results - PTC518 demonstrated dose-dependent reduction of HTT mRNA in preliminary results from Phase 1 healthy volunteer trial - - Total net revenue of $118 million; 73% increase over first...
The following slide deck was published by PTC Therapeutics, Inc. in conjunction with this event. For further details see: PTC Therapeutics (PTCT) PTC518 Huntington's Disease Deep Dive - Slideshow
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2021 Financial Results PR Newswire SOUTH PLAINFIELD, N.J. , April 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference...
Continued Improvements in Motor Milestones in Infants with Type 1 Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi™ - Evrysdi increased survival and reduced need for permanent ventilation - PR Newswire SOUTH PLAINFIELD, N.J. , April 15, ...
PTC Therapeutics Launches the PTC Pinpoint Direct™ Program for Patient-Initiated Genetic Testing - Provides easier access to genetic testing for patients with symptoms or diagnosis of cerebral palsy at no charge - PR Newswire SOUTH PLAINFIELD, N.J. , Apr...
Gene therapy concern Solid Biosciences looks to be taking a meaningful step forward in its Phase 1/2 Duchenne muscular dystrophy trial, after dosing only seven patients in 3 1/2 years. Although Sarepta Therapeutics (SRPT) suffered a setback with its therapy in January 2021, Pfizer...
PTC Therapeutics Received Gallup's "Don Clifton Strengths-Based Culture" Award PR Newswire SOUTH PLAINFIELD, N.J. , April 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been named a winner of the 2021 "Don Clif...
PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar PR Newswire SOUTH PLAINFIELD, N.J. , April 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington di...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....